Methylglyoxal bis(guanylhydrazone) dihydrochloride | 7059-23-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Methylglyoxal bis(guanylhydrazone) dihydrochloride
• 英文别名: 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine;dihydrochloride
• CAS: 7059-23-6
• 化学式: C5H14Cl2N8
• 分子量: 257.12
• InChiKey: VVTBQCXLZQYGQE-PVTAQEPXSA-N

物化性质

• 熔点：
  256 °C (decomp)
• 溶解度：
  溶于水（大于 25 mg/ml）。
• 稳定性/保质期：

  Solution: A solution of 100 mg/mL in water stored at room temperature for 44 days showed no decomposition.

计算性质

• 辛醇/水分配系数(LogP)：
  -1.26
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  154
• 氢给体数：
  6
• 氢受体数：
  4

文献信息

• COMPOSITIONS OF COMPOUNDS AND USES THEREOF
  申请人：VM Oncology LLC

  公开号：US20150218132A1

  公开（公告）日：2015-08-06

  The present disclosure relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same. The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, Alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

  本公开涉及新型合成取代杂环化合物和含有这些化合物的药物组合物。该公开进一步涉及利用这些化合物治疗和/或预防某些类型的癌症、疼痛、炎症、再狭窄、动脉粥样硬化、牛皮癣、血栓形成、阿尔茨海默病、与失髓鞘形成或脱髓鞘有关的疾病、紊乱、损伤或功能障碍。
• [EN] CRYSTALLINE FORMS OF TYROSINE KINASE INHIBITORS AND THEIR SALTS<br/>[FR] FORMES CRISTALLINES D'INHIBITEURS DE LA TYROSINE KINASE ET LEURS SELS
  申请人：VM PHARMA LLC

  公开号：WO2016043975A1

  公开（公告）日：2016-03-24

  The disclosure relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.

  该披露涉及钠4-((3-(4-环己基哌嗪-1-基)-6-氧代-6H-蒽[1,9-cd]异噁唑-5-基)氨基)苯甲酸的各种多形态和非晶形态，包括多形态A、多形态的混合物，其制备方法以及在含有该物质的药物组合物中的使用。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• [EN] NOVEL CRYSTALLINE FORMS<br/>[FR] NOUVELLES FORMES CRISTALLINES
  申请人：VM THERAPEUTICS LLC

  公开号：WO2014143915A1

  公开（公告）日：2014-09-18

  The present invention relates to novel crystalline polymorphic forms of 3-(2-4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)-2-methyl-4H-pyrido[1,2-α]pyrimidin-4-one.The present invention also includes the methods of making crystalline polymorphic forms thereof and the use thereof for preparing a pharmaceutical composition.

  本发明涉及一种新的晶态多形形式的3-(2-4-[(4-氟苯基)羰基]哌啶-1-基}乙基)-2-甲基-4H-吡啶[1,2-α]嘧啶-4-酮。本发明还包括制备晶态多形形式的方法以及用于制备药物组合物的使用方法。
• N-substituted Dithiocarbamates for the Treatment of Biological Disorders
  申请人：AtheroGenics, Inc.

  公开号：US20030176496A1

  公开（公告）日：2003-09-18

  Abstract of Disclosure N-substituted dithiocarbamate esters in which the amine function bears a hydrogen are provides, as are methods for using the compounds in the treatment of cellular hyperproliferation and VCAM-1 mediated disease. Particularly provided is a method of treating a hyperproliferative disorder such as cancer comprising administering an antiproliferative agent in combination with a potentiating effective amount of a N-substituted dithiocarbamate ester. Also provided are methods of using the compounds in the treatment of VCAM-1 mediated diseases such as inflammation and carrdiovascular disease.

  本申请提供了氨基功能带有氢的N-取代二硫代氨基甲酸酯化合物，并提供了使用这些化合物治疗细胞增殖过度和VCAM-1介导疾病的方法。特别提供了一种治疗增殖过度性疾病，如癌症的方法，包括在抗增殖剂的基础上与N-取代二硫代氨基甲酸酯的增强有效量联合给药。还提供了使用这些化合物治疗VCAM-1介导疾病，如炎症和心血管疾病的方法。